Sun Pharmaceutical Industries Limited share price
NSE: SUNPHARMA · BSE: 524715 · ISIN INE044A01036
Key numbers
- Market cap
- ₹ 4,44,405 Cr
- Current price
- ₹ 1,852.20
- 52-week high / low
- ₹ 2,047 / 1,580
- Stock P/E
- 36.8
- Book value
- ₹ 348.3
- Dividend yield
- 0.86%
- ROCE
- 19.0%
- ROE
- 14.7%
- Debt to equity
- 0.06
- Sales growth (3 yrs)
- 10.4%
- Profit growth (3 yrs)
- 10.6%
- 1-year return
- 13.8%
About Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; specialty medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers generics and APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India.
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 12,816 | 13,786 | 15,469 | 14,560 | 15,184 |
| Operating profit | 3,425 | 4,073 | 4,795 | 3,527 | 4,296 |
| Net profit | 2,150 | 2,279 | 3,369 | 2,714 | 2,895 |
| EPS (₹) | 9.00 | 9.50 | 14.00 | 11.30 | 12.10 |
Investor presentation summary (2026-09-22)
AI summary of the presentation · tone: Positive · source document
Key numbers
- FY26 sales: Rs 168,242 mn
- EBITDA: Rs 177,314 mn (30.3% margin)
Guidance & outlook
- result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”,
- FY26 sales: Rs 111,865 mn
Growth & demand
- strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning
- Revenue composition and growth highlights1
Margins & costs
- Gross Margin # EBITDA Margin
- Adjusted Net Profit Margin EBITDA Margin
Capex & expansion
- Acquired outstanding shares of Taro, now a 100% subsidiary of SunFY24
- # FY22 - Adjusted for Rs 43.9 Bn provision (for US litigation related to Ranbaxy Meijer & Others Rs 39,357 mn, Japan (plant) loss Rs 382 mn, Dexasite impairment Rs 1,503 mn., US MDL (Taro) Rs 3,465 mn (after adjusting for
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.